ATE365801T1 - Modulierung durch il-tif/interleukin-21 - Google Patents

Modulierung durch il-tif/interleukin-21

Info

Publication number
ATE365801T1
ATE365801T1 AT01952260T AT01952260T ATE365801T1 AT E365801 T1 ATE365801 T1 AT E365801T1 AT 01952260 T AT01952260 T AT 01952260T AT 01952260 T AT01952260 T AT 01952260T AT E365801 T1 ATE365801 T1 AT E365801T1
Authority
AT
Austria
Prior art keywords
molecules
nucleic acid
proteins
interleukin
tif
Prior art date
Application number
AT01952260T
Other languages
English (en)
Inventor
Laure Dumoutier
Jean-Christophe Renauld
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE365801T1 publication Critical patent/ATE365801T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
AT01952260T 2000-07-27 2001-06-27 Modulierung durch il-tif/interleukin-21 ATE365801T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62661700A 2000-07-27 2000-07-27

Publications (1)

Publication Number Publication Date
ATE365801T1 true ATE365801T1 (de) 2007-07-15

Family

ID=24511131

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01952260T ATE365801T1 (de) 2000-07-27 2001-06-27 Modulierung durch il-tif/interleukin-21
AT07002409T ATE478148T1 (de) 2000-07-27 2001-06-27 Verwendung von il-10 rezeptor beta antagonistische antikörper zur hemmung einer il- tif/il-21 induktion von akutphasen-proteine

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07002409T ATE478148T1 (de) 2000-07-27 2001-06-27 Verwendung von il-10 rezeptor beta antagonistische antikörper zur hemmung einer il- tif/il-21 induktion von akutphasen-proteine

Country Status (9)

Country Link
EP (2) EP1305419B1 (de)
JP (1) JP4113773B2 (de)
CN (3) CN100448994C (de)
AT (2) ATE365801T1 (de)
AU (1) AU7303301A (de)
CA (1) CA2416820A1 (de)
DE (2) DE60142861D1 (de)
ES (1) ES2349312T3 (de)
WO (1) WO2002010393A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US7307161B1 (en) 1999-04-28 2007-12-11 Genetics Institute, Llc Human Gil-19/AE289 polynucleotides
US20030170823A1 (en) 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
US20030023033A1 (en) * 2001-07-26 2003-01-30 Laure Dumoutier Novel class II cytokine receptors and uses thereof
US20030012788A1 (en) 2000-07-27 2003-01-16 Jean-Christophe Renauld Method for influencing kinase pathways with IL-22
EP1326974B1 (de) * 2000-10-13 2006-12-27 Eli Lilly And Company Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten
US7638604B2 (en) 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
EP1546358A4 (de) 2002-03-22 2006-06-07 Zymogenetics Inc Anti-il-tif-antikörper und verfahren zur verwendung bei entzündung
WO2004003156A2 (en) 2002-07-01 2004-01-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Il-21 as a regulator of immunoglobin production
WO2004024076A2 (en) * 2002-09-11 2004-03-25 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
EP1731163A2 (de) * 2002-10-11 2006-12-13 Novo Nordisk A/S Behandlung von allergischen Zuständen durch Verwendung von IL-21
WO2004032953A1 (en) * 2002-10-11 2004-04-22 Novo Nordisk A/S Treatment of allergic conditions by use of il 21
KR20060022289A (ko) * 2003-06-23 2006-03-09 제네틱스 인스티튜트, 엘엘씨 인터류킨-22 에 대한 항체 및 그의 용도
JP2009518314A (ja) 2005-12-02 2009-05-07 ジェネンテック・インコーポレーテッド Ｉｌ−２２に結合する抗体およびｉｌ−２２ｒに結合する抗体を含む、サイトカインシグナリングに関連する疾患および障害の処置のための組成物および方法
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
IT1404858B1 (it) 2011-02-21 2013-12-09 Milano Politecnico Supporto anti-sismico.
KR20230061392A (ko) * 2020-08-05 2023-05-08 신테카인, 인크. 수용체 쌍형성과 관련된 조성물 및 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843697A (en) 1996-07-17 1998-12-01 University Of Medicine And Dentistry Of New Jersey Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein
DE19848683B4 (de) 1998-10-22 2004-05-06 Basf Ag Verbundschichtplatte
US6331613B1 (en) * 1998-10-26 2001-12-18 Ludwig Institue For Cancer Research Isolated nucleic acid molecules which encode T cell inducible factors (TIFS), the proteins encoded, and uses thereof
NZ515678A (en) * 1999-04-28 2004-01-30 Genetics Inst Human GIL-19/AE289 proteins and polynucleotides encoding same
AU5047600A (en) * 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
CA2393369A1 (en) * 1999-12-03 2001-06-07 Zymogenetics, Inc. Human cytokine receptor

Also Published As

Publication number Publication date
CN100497628C (zh) 2009-06-10
EP1806404B1 (de) 2010-08-18
CN100448994C (zh) 2009-01-07
CA2416820A1 (en) 2002-02-07
EP1305419B1 (de) 2007-06-27
WO2002010393A3 (en) 2003-01-30
CN1796558A (zh) 2006-07-05
ES2349312T3 (es) 2010-12-29
DE60129137D1 (de) 2007-08-09
ATE478148T1 (de) 2010-09-15
JP4113773B2 (ja) 2008-07-09
EP1305419A2 (de) 2003-05-02
DE60142861D1 (de) 2010-09-30
CN1443241A (zh) 2003-09-17
AU7303301A (en) 2002-02-13
CN101423551A (zh) 2009-05-06
EP1806404A1 (de) 2007-07-11
WO2002010393A2 (en) 2002-02-07
JP2004504842A (ja) 2004-02-19

Similar Documents

Publication Publication Date Title
DE60129137D1 (de) Modulierung durch il-tif/interleukin-21
ATE469911T1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
BRPI0512396A (pt) polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
ATE227739T1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
ATE500323T1 (de) Subtilisin-variante
CY1112198T1 (el) Αναλογα κομπστατινης με βελτιωμενη δραστικοτητα
EP1019365A4 (de) Zubereitungen zur abgabe von negativ geladenen molekülen
ATE536369T1 (de) Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung
DK1458760T3 (da) Indfangede bindingsproteiner som biosensorer
NO20043259L (no) Bindingsproteiner som biosensorer
DK1015586T3 (da) TIE-receptortyrosinkinaseligandhomologer
DK0912176T3 (da) Anvendelse af pyridylalkan-, pyridylalken- og/eller pyridylalkynsyreamider til behandling af tumorer eller immunosuppression
ATE507822T1 (de) Stabilisierte zusammensetzungen von faktor-vii- polypeptiden
NO20082783L (no) Induserbare ekspresjonssystemer
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DK1536778T3 (da) Proteiner, der binder til cross-beta-strukturholdigt amyloid og fremgangsmåder til modulation af cross-beta-strukturen, dens dannelse og dens associerede toksicitet
BR0312521A (pt) Métodos para a separação e a purificação de fibrinogênio e de pelo menos uma outra proteìna e para a co-purificação de fibrinogênio e de fator xiii, uso de cromatografia de afinidade com ìon de metal imobilizado, fibrinogênio, kit farmacêutico, e, formulações farmacêutica e de fibrinogênio liofilizado
GEAP202516650A (en) Stabilized pre-fusion hmpv fusion proteins
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
ATE461453T1 (de) Nukleinsäuresequenz und protein, das eine rolle bei der zellulären alterung spielt
DK1465927T3 (da) BAG3-antistoffer til anvendelse til forskning, diagnostik og behandling af sygdomme, der omfatter celledød
ATE532793T1 (de) Verfahren zur herstellung von molekülen mit verminderter immunogenität
WO2004108749A3 (en) Binding peptides: methods for their generation and use
DK1387854T3 (da) SFRP og peptidmotiver som interagerer med SFRP og fremgangsmåder til anvendelse deraf
EA200401032A1 (ru) Антиинфарктные молекулы

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
REN Ceased due to non-payment of the annual fee
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties